{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T21:12:34Z","timestamp":1783977154084,"version":"3.55.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"a Grant-in-Aid for Early-Career Scientists from the Japan Society for the Promotion of Science","award":["25K19566"],"award-info":[{"award-number":["25K19566"]}]},{"name":"he Shin-nihon Foundation of Advanced Medical Treatment Research"},{"name":"he Kaibara Morikazu Medical Science Promotion Foundation"},{"name":"a Grant-in-Aid for Scientific Research (C) from the Japan Society for the Promotion of Science","award":["24K11542"],"award-info":[{"award-number":["24K11542"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-07061-6","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T23:13:17Z","timestamp":1778281997000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Gilteritinib response in acute myeloid leukemia harboring a rare FLT3 juxtamembrane domain mutation with subsequent clonal evolution"],"prefix":"10.1007","volume":"105","author":[{"given":"Fumihiko","family":"Nakao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Shima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Takigawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Semba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiaki","family":"Jinnouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuji","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Odawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikane","family":"Kikushige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Akashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"key":"7061_CR1","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1056\/NEJMc1608739","volume":"375","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Dohner H, Campbell PJ (2016) Genomic Classification in Acute Myeloid Leukemia. N Engl J Med 375:900\u2013901. https:\/\/doi.org\/10.1056\/NEJMc1608739","journal-title":"N Engl J Med"},{"key":"7061_CR2","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","volume":"392","author":"NJ Short","year":"2018","unstructured":"Short NJ, Rytting ME, Cortes JE (2018) Acute myeloid leukaemia. Lancet 392:593\u2013606. https:\/\/doi.org\/10.1016\/S0140-6736(18)31041-9","journal-title":"Lancet"},{"key":"7061_CR3","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1152\/physrev.00029.2018","volume":"99","author":"JU Kazi","year":"2019","unstructured":"Kazi JU, Ronnstrand L (2019) FMS-like Tyrosine Kinase 3\/FLT3: From Basic Science to Clinical Implications. Physiol Rev 99:1433\u20131466. https:\/\/doi.org\/10.1152\/physrev.00029.2018","journal-title":"Physiol Rev"},{"key":"7061_CR4","doi-asserted-by":"publisher","first-page":"4263","DOI":"10.1158\/1078-0432.CCR-08-1123","volume":"15","author":"S Meshinchi","year":"2009","unstructured":"Meshinchi S, Appelbaum FR (2009) Structural and functional alterations of FLT3 in acute myeloid leukemia. Clin Cancer Res 15:4263\u20134269. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-1123","journal-title":"Clin Cancer Res"},{"key":"7061_CR5","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/cas.14274","volume":"111","author":"H Kiyoi","year":"2020","unstructured":"Kiyoi H, Kawashima N, Ishikawa Y (2020) FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development. Cancer Sci 111:312\u2013322. https:\/\/doi.org\/10.1111\/cas.14274","journal-title":"Cancer Sci"},{"key":"7061_CR6","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","volume":"381","author":"AE Perl","year":"2019","unstructured":"Perl AE et al (2019) Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. N Engl J Med 381:1728\u20131740. https:\/\/doi.org\/10.1056\/NEJMoa1902688","journal-title":"N Engl J Med"},{"key":"7061_CR7","doi-asserted-by":"publisher","unstructured":"Perl AE et al (2023) Outcomes in Patients with FLT3-Mutated Relapsed\/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy. Transplant Cell Ther 29, 265 e261-265 e210 https:\/\/doi.org\/10.1016\/j.jtct.2022.12.006","DOI":"10.1016\/j.jtct.2022.12.006"},{"key":"7061_CR8","doi-asserted-by":"publisher","first-page":"100905","DOI":"10.1016\/j.blre.2021.100905","volume":"52","author":"JC Zhao","year":"2022","unstructured":"Zhao JC et al (2022) A review of FLT3 inhibitors in acute myeloid leukemia. Blood Rev 52:100905. https:\/\/doi.org\/10.1016\/j.blre.2021.100905","journal-title":"Blood Rev"},{"key":"7061_CR9","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1038\/s41375-024-02382-9","volume":"38","author":"J Wang","year":"2024","unstructured":"Wang J et al (2024) Phase 3 study of gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed\/refractory FLT3-mutated acute myeloid leukemia. Leukemia 38:2410\u20132418. https:\/\/doi.org\/10.1038\/s41375-024-02382-9","journal-title":"Leukemia"},{"key":"7061_CR10","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1182\/bloodadvances.2020002876","volume":"5","author":"DJ Young","year":"2021","unstructured":"Young DJ et al (2021) Deletions in FLT-3 juxtamembrane domain define a new class of pathogenic mutations: case report and systematic analysis. Blood Adv 5:2285\u20132293. https:\/\/doi.org\/10.1182\/bloodadvances.2020002876","journal-title":"Blood Adv"},{"key":"7061_CR11","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/s41375-024-02498-y","volume":"39","author":"N Anabtawi","year":"2025","unstructured":"Anabtawi N et al (2025) Prognostic, biological, and structural implications of FLT3-JMD point mutations in acute myeloid leukemia: an analysis of Alliance studies. Leukemia 39:623\u2013631. https:\/\/doi.org\/10.1038\/s41375-024-02498-y","journal-title":"Leukemia"},{"key":"7061_CR12","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/s1097-2765(03)00505-7","volume":"13","author":"J Griffith","year":"2004","unstructured":"Griffith J et al (2004) The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. Mol Cell 13:169\u2013178. https:\/\/doi.org\/10.1016\/s1097-2765(03)00505-7","journal-title":"Mol Cell"},{"key":"7061_CR13","doi-asserted-by":"publisher","first-page":"3700","DOI":"10.1182\/blood-2005-06-2596","volume":"107","author":"C Reindl","year":"2006","unstructured":"Reindl C et al (2006) Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML. Blood 107:3700\u20133707. https:\/\/doi.org\/10.1182\/blood-2005-06-2596","journal-title":"Blood"},{"key":"7061_CR14","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1182\/blood.2020007626","volume":"137","author":"LK Schmalbrock","year":"2021","unstructured":"Schmalbrock LK et al (2021) Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. Blood 137:3093\u20133104. https:\/\/doi.org\/10.1182\/blood.2020007626","journal-title":"Blood"},{"key":"7061_CR15","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1158\/2159-8290.CD-18-1453","volume":"9","author":"CM McMahon","year":"2019","unstructured":"McMahon CM et al (2019) Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia. Cancer Discov 9:1050\u20131063. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-1453","journal-title":"Cancer Discov"},{"key":"7061_CR16","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/S1470-2045(17)30416-3","volume":"18","author":"AE Perl","year":"2017","unstructured":"Perl AE et al (2017) Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1\u20132 study. Lancet Oncol 18:1061\u20131075. https:\/\/doi.org\/10.1016\/S1470-2045(17)30416-3","journal-title":"Lancet Oncol"},{"key":"7061_CR17","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1182\/bloodadvances.2020003709","volume":"5","author":"S Stratmann","year":"2021","unstructured":"Stratmann S et al (2021) Genomic characterization of relapsed acute myeloid leukemia reveals novel putative therapeutic targets. Blood Adv 5:900\u2013912. https:\/\/doi.org\/10.1182\/bloodadvances.2020003709","journal-title":"Blood Adv"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07061-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07061-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07061-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T21:01:56Z","timestamp":1783976516000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07061-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":17,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["7061"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07061-6","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]},"assertion":[{"value":"29 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was carried out according to the Declaration of Helsinki and was approved by the ethics committees of Kyushu University Graduate School and the Faculty of Medicine (approval no. 721-02).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent for publication of this case report and accompanying images was obtained from the patient\u2019s family.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"311"}}